The Lncrna-TUG1/EZH2 Axis Promotes Pancreatic Cancer Cell Proliferation, Migration and EMT Phenotype Formation Through Sponging Mir-382.

作者: Liang Zhao , Hongwei Sun , Hongru Kong , Zongjing Chen , Bicheng Chen

DOI: 10.1159/000479990

关键词:

摘要: Background/Aims: Pancreatic carcinoma (PC) is the one of most common and malignant cancers worldwide. LncRNA taurine upregulated gene 1 (TUG1) was initially identified as a transcript by taurine, abnormal expression TUG1 has been reported in many cancers. However, biological role molecular mechanism PC still needs further investigation. Methods: Quantitative real-time PCR (qRT-PCR) performed to measure cell lines tissues. MTT colony formation assays were used effect on proliferation. A wound healing assay, transwell assay western blot employed determine migration epithelial mesenchymal transition (EMT) phenotype. RNA-binding protein immunoprecipitation (RIP) biotin-avidin pulldown system confirm interaction between miR-328 TUG1. array analysis using clinical samples RT-qPCR suggested that enhancer zeste homolog 2 (EZH2) target miR-382 PC. Results: In this study, we overexpressed tissues lines, high predicted poor prognosis. Further experiments revealed promoted proliferation, contributed EMT formation, whereas silenced led opposing results. Additionally, luciferase reporter assays, an RIP RNA-pulldown demonstrated could competitively sponge thereby regulate EZH2. Conclusion: Collectively, these findings functions oncogenic lncRNA promotes tumor progression, at least partially, functioning endogenous ‘sponge’ competing for binding miRNA

参考文章(36)
Bin Song, Kailian Zheng, Hongyun Ma, Anan Liu, Wei Jing, Chenghao Shao, Gang Li, Gang Jin, miR-429 determines poor outcome and inhibits pancreatic ductal adenocarcinoma growth by targeting TBK1. Cellular Physiology and Biochemistry. ,vol. 35, pp. 1846- 1856 ,(2015) , 10.1159/000373995
E-b Zhang, D-d Yin, M Sun, R Kong, X-h Liu, L-h You, L Han, R Xia, K-m Wang, J-s Yang, W De, Y-q Shu, Z-x Wang, P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression Cell Death and Disease. ,vol. 5, ,(2014) , 10.1038/CDDIS.2014.201
Weifeng Song, Qi Li, Lei Wang, Liwei Wang, Modulation of FoxO1 Expression by miR-21 to Promote Growth of Pancreatic Ductal Adenocarcinoma Cellular Physiology and Biochemistry. ,vol. 35, pp. 184- 190 ,(2015) , 10.1159/000369686
M. M. Javle, J. F. Gibbs, K. K. Iwata, Y. Pak, P. Rutledge, J. Yu, J. D. Black, D. Tan, T. Khoury, Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Annals of Surgical Oncology. ,vol. 14, pp. 3527- 3533 ,(2007) , 10.1245/S10434-007-9540-3
Kennichi Satoh, Shin Hamada, Tooru Shimosegawa, Involvement of epithelial to mesenchymal transition in the development of pancreatic ductal adenocarcinoma Journal of Gastroenterology. ,vol. 50, pp. 140- 146 ,(2015) , 10.1007/S00535-014-0997-0
Bin Song, Chaoxiong Zhang, Gang Li, Gang Jin, Cong Liu, None, MiR-940 inhibited pancreatic ductal adenocarcinoma growth by targeting MyD88. Cellular Physiology and Biochemistry. ,vol. 35, pp. 1167- 1177 ,(2015) , 10.1159/000373941
Leonardo Salmena, Laura Poliseno, Yvonne Tay, Lev Kats, Pier Paolo Pandolfi, A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language? Cell. ,vol. 146, pp. 353- 358 ,(2011) , 10.1016/J.CELL.2011.07.014
Katherine E. Poruk, Matthew A. Firpo, Douglas G. Adler, Sean J. Mulvihill, Screening for pancreatic cancer: why, how, and who? Annals of Surgery. ,vol. 257, pp. 17- 26 ,(2013) , 10.1097/SLA.0B013E31825FFBFB
Qiang Zhang, Pei-Liang Geng, Pei Yin, Xiao-Lin Wang, Jin-Peng Jia, Jie Yao, Down-regulation of long non-coding RNA TUG1 inhibits osteosarcoma cell proliferation and promotes apoptosis. Asian Pacific Journal of Cancer Prevention. ,vol. 14, pp. 2311- 2315 ,(2013) , 10.7314/APJCP.2013.14.4.2311
Anastasios Stathis, Malcolm J. Moore, Advanced pancreatic carcinoma: current treatment and future challenges. Nature Reviews Clinical Oncology. ,vol. 7, pp. 163- 172 ,(2010) , 10.1038/NRCLINONC.2009.236